Alopecia

Q32 Bio reported bempikibart reduced SALT scores by 35.3% and produced a SALT-20 response in 40.0% of patients at week 36 in the SIGNAL-AA phase 2a trial.

AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.

HCW9302 selectively expands Treg cells to suppress autoreactive follicular inflammation without broad immunosuppression.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

AI analysis of 187,016 menopausal women links hair loss severity to thyroid disease, gut symptoms, scalp inflammation, and genetics, supporting broader diagnostic workups beyond hormones.

Lakshi M. Aldredge, MSN, ANP-BC, DCNP, discusses late-breaking data preseneted at SDNP on novel immune-mediated therapies for atopic dermatitis, alopecia areata, and hidradenitis suppurativa.

Maryanne Makredes Senna, MD, reviews early-onset efficacy, favorable tolerability, and high rates of patient-reported improvement associated with extended-release oral minoxidil data.

Maryanne Makredes Senna, MD, shares why mineral sunscreens matter for patients with frontal fibrosing alopecia, and why reprimanding sun-seekers may be more detrimental to patient care.

Maryanne Makredes Senna, MD, discusses emerging data suggesting extended-release oral minoxidil tablets may improve efficacy while minimizing cardiovascular adverse effects in patients with androgenetic alopecia.

Dermatology Times' editor in chief highlights essential late-breaker data from AAD 2026, including upadacitinib, rezpegaldesleukin, icotrokinra, zasocitinib, envudeucitinib, sonelokimab, and more.

Turmeric and curcumin supplements used for hair loss are increasingly associated with rare but serious cases of liver injury.

New sham-controlled trial finds niostem's at-home wearable using low-level electrical stimulation boosts hair density in men, with minimal adverse effects.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.

Weekly microneedling combined with daily topical 5% minoxidil produced statistically significant hair density gains in 40 women with female pattern hair loss.

The application is based on phase 3 UP-AA trial data showing significant hair regrowth in patients with severe alopecia areata.

Part A of Study '302' demonstrated statistically significant and clinically meaningful hair growth in men with androgenetic alopecia, with a favorable safety profile and no cardiac adverse events.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.